Drug Trial Radar · NCT05406401
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 14, 2022
Primary completion
Apr 26, 2029
Study completion Apr 26, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease. The efficacy expansion phase is to determine the efficacy of the RP2D of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease.
Conditions
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
Interventions
Zilovertamab VedotinBiological
IV infusion
CyclophosphamideDrug
IV infusion
DoxorubicinDrug
IV infusion
RituximabBiological
IV infusion
Rituximab BiosimilarBiological
IV infusion
PrednisoneDrug
IV or oral administration (per local guidelines)
PrednisoloneDrug
IV or oral administration (per local guidelines)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1Time frame: Cycle 1 (up to 21 days)
- Number of Participants Who Experienced At Least One AETime frame: Up to approximately 8 months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 5.5 months
- Complete Response Rate (CRR) per Lugano Response CriteriaTime frame: Up to approximately 60 months
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
BC Cancer Victoria-Clinical Trials Unit ( Site 0105)
Victoria, British Columbia, Canada
William Osler Health System ( Site 0106)
Toronto, Ontario, Canada
Hopital du Sacre-Coeur de Montreal ( Site 0108)
Montreal, Quebec, Canada
Hadassah Medical Center ( Site 0401)
Jerusalem, Israel
Sheba Medical Center-Hemato Oncology ( Site 0400)
Ramat Gan, Israel
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant
Alessandria, Italy
Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 0306)
Rome, Lazio, Italy
Ospedale San Raffaele-Unità Linfomi ( Site 0305)
Milan, Lombardy, Italy
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0307)
Palermo, Sicily, Italy
Azienda Ospedaliera Universitaria Careggi-SOD Ematologia ( Site 0308)
Florence, Tuscany, Italy
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 0503)
Lodz, Łódź Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site
Warsaw, Masovian Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0504)
Gdansk, Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0505)
Gliwice, Silesian Voivodeship, Poland
Seoul National University Hospital ( Site 0201)
Seoul, South Korea
Samsung Medical Center ( Site 0200)
Seoul, South Korea
Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0700)
Madrid, Spain
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Hematology ( Site 0704)
Seville, Andalusia, Spain
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 0703)
L'Hospitalet Del Llobregat, Barcelona, Spain
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 0801)
Ankara, Turkey (Türkiye)
Trakya University ( Site 0805)
Edirne, Turkey (Türkiye)
Mega Medipol-Hematology ( Site 0808)
Stanbul, Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.